Company / R&D per Share
Fulcrum Therapeutics, Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$885.53
FY2025
5-year range
$885.53 / $1971.13
FY2021-FY2025
Trend
-13.4%
vs FY2024
Sector context
#3 of 208
Health Care
What the data says
Among 208 Health Care companies, Fulcrum Therapeutics, Inc. is in the top 1% for r&d per share. R&D per Share has declined for 7 consecutive years, from $20035.00 in FY2018 to $885.53 in FY2025.
Based on SEC 10-K filings.
885.53 in FY2025 with a 5-year CAGR of -17.6%. Ranks 3rd among 208 companies in Health Care.
Declined from $1171.11 to $885.53 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -19.6%
- 5-Year CAGR
- -17.6%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 208This company $885.53 Sector average $28.82
▼
+2972.8% above sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s r&d per share has declined for 7 consecutive years.
- In FY2025, r&d per share decreased 13.4% year-over-year.
- Ranks #3 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $885.53 | -13.4% |
| FY2024 | $1022.62 | -12.7% |
| FY2023 | $1171.11 | -31.4% |
| FY2022 | $1706.61 | -13.4% |
| FY2021 | $1971.13 | -15.4% |
| FY2020 | $2328.71 | -63.8% |
| FY2019 | $6434.18 | -67.9% |
| FY2018 | $20035.00 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026